Based on the InflaRx N.V. stock forecast from 1 analysts, the average analyst target price for InflaRx N.V. is USD 8.00 over the next 12 months. InflaRx N.V.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of InflaRx N.V. is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, InflaRx N.V.’s stock price was USD 1.71. InflaRx N.V.’s stock price has changed by +11.76% over the past week, +13.25% over the past month and +14.00% over the last year.
No recent analyst target price found for InflaRx N.V.
No recent average analyst rating found for InflaRx N.V.
Company Overview InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Read Less
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory d...Read More
Frequently Asked Questions About InflaRx N.V. (IFRX) Stock
Based on ratings from 1 analysts InflaRx N.V.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on IFRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IFRX is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
IFRX stock's Price/Earning ratio is -99,999.99.
Our analysis grades IFRX stock's Price / Earning ratio at A+. This means that IFRX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IFRX may be undervalued for its sector.
The last closing price of IFRX's stock was USD 1.71.
The most recent market capitalization for IFRX is USD 0.09B.
Based on targets from 1 analysts, the average taret price for IFRX is projected at USD 8.00 over the next 12 months.
This means that IFRX's stock price may go up by +367.84% over the next 12 months.
We can't find any ETFs which contains InflaRx N.V.'s stock.
As per our most recent records InflaRx N.V. has 62 Employees.
InflaRx N.V.'s registered address is Winzerlaer Str. 2, Jena, Germany, 07745.
You can get more information about it from InflaRx N.V.'s website at https://www.inflarx.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About InflaRx N.V. (IFRX) Stock
Based on ratings from 1 analysts InflaRx N.V.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on IFRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IFRX is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
IFRX stock's Price/Earning ratio is -99,999.99.
Our analysis grades IFRX stock's Price / Earning ratio at A+. This means that IFRX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IFRX may be undervalued for its sector.
The last closing price of IFRX's stock was USD 1.71.
The most recent market capitalization for IFRX is USD 0.09B.
Based on targets from 1 analysts, the average taret price for IFRX is projected at USD 8.00 over the next 12 months.
This means that IFRX's stock price may go up by +367.84% over the next 12 months.
We can't find any ETFs which contains InflaRx N.V.'s stock.
As per our most recent records InflaRx N.V. has 62 Employees.
InflaRx N.V.'s registered address is Winzerlaer Str. 2, Jena, Germany, 07745.
You can get more information about it from InflaRx N.V.'s website at https://www.inflarx.de.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IFRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
